WO2007051811A2 - Pharmaceutical use of substituted amides - Google Patents
Pharmaceutical use of substituted amides Download PDFInfo
- Publication number
- WO2007051811A2 WO2007051811A2 PCT/EP2006/068017 EP2006068017W WO2007051811A2 WO 2007051811 A2 WO2007051811 A2 WO 2007051811A2 EP 2006068017 W EP2006068017 W EP 2006068017W WO 2007051811 A2 WO2007051811 A2 WO 2007051811A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbonyl
- alkyl
- aza
- hydroxy
- bicyclo
- Prior art date
Links
- 0 *N(*)C(c(cc1)cc([N+]([O-])=O)c1N)=O Chemical compound *N(*)C(c(cc1)cc([N+]([O-])=O)c1N)=O 0.000 description 3
- CJQNJRRDTPULTL-UHFFFAOYSA-N C(C1)C2CNCC1C2 Chemical compound C(C1)C2CNCC1C2 CJQNJRRDTPULTL-UHFFFAOYSA-N 0.000 description 1
- DGGKXQQCVPAUEA-UHFFFAOYSA-N C(C1)C2NC1CCC2 Chemical compound C(C1)C2NC1CCC2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
- GUWZBFCQRKWQSI-UHFFFAOYSA-N CCC(CCNC(NNC(CCC(C1)C(N2C(CCCC3)C3CCC2)O)C1NC)=C)C(O)O Chemical compound CCC(CCNC(NNC(CCC(C1)C(N2C(CCCC3)C3CCC2)O)C1NC)=C)C(O)O GUWZBFCQRKWQSI-UHFFFAOYSA-N 0.000 description 1
- AOWLQKIARVCZSA-UHFFFAOYSA-N C[n]1c(ccc(C(N2CCCCCCC2)=O)c2)c2nc1 Chemical compound C[n]1c(ccc(C(N2CCCCCCC2)=O)c2)c2nc1 AOWLQKIARVCZSA-UHFFFAOYSA-N 0.000 description 1
- ZZNAYFWAXZJITH-UHFFFAOYSA-N Nc(ccc(C(O)=O)c1)c1[N+]([O-])=O Chemical compound Nc(ccc(C(O)=O)c1)c1[N+]([O-])=O ZZNAYFWAXZJITH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Definitions
- the present invention relates to use of substituted amides and pharmaceutical com- positions comprising the same for treating disorders where it is desirable to modulate the activity of 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 (1 1 ⁇ HSD1 ).
- the present invention also relates to novel substituted amides, to their use in therapy, to pharmaceutical compositions comprising the same, to the use of said compounds in the manufacture of medicaments, and to therapeutic methods comprising the administration of the compounds.
- the present com- pounds modulate the activity of 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 (1 1 ⁇ HSD1 ) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
- the metabolic syndrome is a major global health problem. In the US, the prevalence in the adult population is currently estimated to be approximately 25%, and it continues to increase both in the US and worldwide.
- the metabolic syndrome is characterised by a combination of insulin resistance, dyslipidemia, obesity and hypertension leading to increased morbidity and mortality of cardiovascular diseases. People with the metabolic syndrome are at increased risk of developing frank type 2 diabetes, the prevalence of which is equally escalating.
- 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 (1 1 ⁇ HSD1 ) catalyses the local generation of active glucocorticoid in several tissues and organs including predominantly the liver and adipose tissue, but also e.g. skeletal muscle, bone, pancreas, endothelium, ocular tissue and certain parts of the central nervous system.
- 1 1 ⁇ HSD1 serves as a local regulator of glucocorticoid actions in the tissues and organs where it is expressed (Tannin et al., J. Biol.
- 1 1 ⁇ HSD1 The role of 1 1 ⁇ HSD1 in the metabolic syndrome and type 2 diabetes is supported by several lines of evidence.
- treatment with the non-specific 1 1 ⁇ HSD1 inhibitor car- benoxolone improves insulin sensitivity in lean healthy volunteers and people with type 2 diabetes.
- 1 1 ⁇ HSD1 knock-out mice are resistant to insulin resistance induced by obesity and stress. Additionally, the knock-out mice present with an anti-atherogenic lipid profile of decreased VLDL triglycerides and increased HDL-cholesterol.
- mice that overexpress 1 1 ⁇ HSD1 in adipocytes develop insulin resistance, hyperlipidemia and vis- ceral obesity, a phenotype that resembles the human metabolic syndrome (Andrews et al., J. Clin. Endocrinol. Metab., 88, 285 (2003); Walker et al., J. Clin. Endocrinol. Metab., 80, 3155 (1995); Morton et al., J. Biol. Chem., 276, 41293 (2001 ); Kotelevtsev et al., Proc. Natl. Acad.
- 1 1 ⁇ HSD1 promotes the features of the metabolic syndrome by increasing hepatic expression of the rate-limiting enzymes in gluconeogenesis, namely phosphoenolpyuvate carboxykinase and glucose-6-phosphatase, promoting the differentiation of preadipocytes into adipocytes thus facilitating obesity, directly and indirectly stimulat- ing hepatic VLDL secretion, decreasing hepatic LDL uptake and increasing vessel contractility (Kotelevtsev et al., Proc. Natl. Acad. ScL USA, 94, 14924(1997); Morton et al., J. Biol. Chem.
- WO 01/90090, WO 01/90091 , WO 01/90092, WO 01/90093 and WO 01/90094 dis- closes various thiazol-sulfonamides as inhibitors of the human 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 enzyme, and further states that said compounds may be useful in treating diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders and depression.
- substituted amides that modulate the activity of 1 1 ⁇ HSD1 lead- ing to altered intracellular concentrations of active glucocorticoid. More specifically, the present compounds inhibit the activity of 1 1 ⁇ HSD1 leading to decreased intracellular concentrations of active glucocorticoid.
- the present compounds can be used to treat disorders where a decreased level of active intracellular glucocorticoid is desirable, such as e.g.
- One object of the present invention is to provide compounds, pharmaceutical compositions and use of compounds that modulate the activity of 1 1 ⁇ HSD1 .
- halo includes fluorine, chlorine, bromine, and iodine.
- trihalomethyl includes trifluoromethyl, trichloromethyl, tribromomethyl, and triiodomethyl.
- trihalomethoxy includes trifluorometoxy, trichlorometoxy, tribromometoxy, and triiodometoxy.
- alkyl includes d-C 8 straight chain saturated and methylene aliphatic hydrocarbon groups and C 3 -C 8 branched saturated hydrocarbon groups having the specified number of carbon atoms.
- this definition includes methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, isopropyl (i-Pr), isobutyl (i-Bu), te/t-butyl (/-Bu), sec-butyl (s- Bu), isopentyl, and neopentyl.
- alkenyl includes C 2 -C 6 straight chain unsaturated aliphatic hydrocarbon groups and branched C 3 -C 6 unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- this definition includes ethenyl, propenyl, butenyl, pentenyl, hexenyl, methylpropenyl, and methylbutenyl.
- alkynyl includes C 2 -C 6 straight chain unsaturated aliphatic hydrocarbon groups and C 4 -C 6 branched unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- this definition includes ethynyl, propynyl, butynyl, pentynyl, hexynyl, and methylbutynyl.
- saturated or partially saturated monocyclic, bicyclic, or tricyclic ring system represents but is not limited to aziridinyl, azepanyl, azocanyl, pyrrolinyl, pyrrolidinyl, 2- imidazolinyl, imidazolidinyl, 2-pyrazolinyl, morpholinyl, piperidinyl, thiomorpholinyl, piperaz- inyl, phthalimide, 1 ,2,3,4-tetrahydro-quinolinyl, 1 ,2,3,4-tetrahydro-isoquinolinyl, 1 ,2,3,4- tetrahydro-quinoxalinyl, indolinyl, 1 , 6-aza-bicyclo[3.2.1 ]octane, 2-aza-bicyclo[4.1 .1 ]octane, 2-aza-bicyclo[3.2.1]octanyl, 7-aza-bicyclo
- saturated or partially saturated ring represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooc- tenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl, and tetrahydropyranyl.
- saturated or partially saturated aromatic ring represents cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, and pyrimid- inyl.
- cycloalkyl represents a saturated, mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[3.2.1 ]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, and adamantyl).
- cycloalkylalkyl represents a cycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms or substituted alkyl group as defined above (e.g., cyclopropylmethyl, cyclobutylethyl, and adamantylmethyl).
- cycloalkenyl represents a partially saturated, mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms (e.g., cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl).
- cycloalkylcarbonyl represents a cycloalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., cyclopropyl- carbonyl and cyclohexylcarbonyl).
- cycloalkylalkylcarbonyl represents a cycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms or substituted alkyl group as defined above (e.g., cyclohexylmethylcarbonyl and cycloheptylethylcarbonyl).
- hetcycloalkyl represents a saturated mono-, bi-, tri-, or spirocarbocyclic group having the specified number of atoms with 1 -4 of the specificied number being het- eroatoms or groups selected from nitrogen, oxygen, sulphur, SO, and SO 2 (e.g., tetrahydrofuranyl, tetrahydropyranyl, tertahydrothiopyranyl, piperidine, and pyridzine).
- hetcycloalkylalkyl represents a hetcycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., tetrahy- drofuranylmethyl, tetrahydropyranylethyl, and tertahydrothiopyranylmethyl).
- hetcycloalkylcarbonyl represents a hetcycloalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., 1 - piperidin-4-yl-carbonyl and 1 -(1 ,2,3,4-tetrahydro-isoquinolin-6-yl)carbonyl).
- alkyloxy represents an alkyl group having the indicated number of carbon atoms attached through an oxygen bridge (e.g., methoxy, ethoxy, propyloxy, allyloxy, and cyclohexyloxy).
- alkyloxyalkyl represents an alkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., methyloxy- methyl).
- aryl includes a carbocyclic aromatic ring that is monocyclic, bicyclic, or polycyclic, such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, inde- nyl, pentalenyl, azulenyl, and biphenylenyl.
- Aryl also includes the partially hydrogenated derivatives of the carbocyclic aromatic enumerated above. Examples of partially hydrogenated derivatives include 1 ,2,3,4-tetrahydronaphthyl and 1 ,4-dihydronaphthyl.
- aryh includes phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, and fluorenyl.
- aryl2 includes phenyl, biphenyl, and naphthyl.
- heteroaryl includes pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1 - imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazol-1 -yl, 1 ,2,3-triazol-2- yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thio- phenyl (2-thiophenyl, 3-thiophenyl, 4-thiophenyl, 5-thiophenyl), furany
- arylalkyl represents an aryl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., benzyl, phenylethyl, 3- phenylpropyl, 1 -naphtylmethyl, and 2-(1 -naphtyl)ethyl).
- hetarylalkyl or “hetaralkyl” represents a hetaryl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, and 1 - methyl-1 -(2-pyrimidyl)ethyl).
- aryloxyhetaryl represents an aryloxy group as defined above attached through a hetaryl group (e.g., 2-phenoxy-pyridyl).
- aryloxy represents an aryl group as defined above attached through an oxygen bridge (e.g., phenoxy and naphthyloxy).
- hetaryloxy represents a hetaryl group as defined above attached through an oxygen bridge (e.g., 2-pyridyloxy).
- arylalkyloxy represents an arylalkyl group as defined above attached through an oxygen bridge (e.g., phenethyloxy and naphthylmethyloxy).
- hetarylalkyloxy represents a hetarylalkyl group as defined above attached through an oxygen bridge (e.g., 2-pyridylmethyloxy).
- alkyloxycarbonyl represents an alkyloxy group as defined above attached through a carbonyl group (e.g., methylformiat and ethylformiat).
- aryloxycarbonyl represents an aryloxy group as defined above attached through a carbonyl group (e.g., phenylformiat and 2-thiazolylformiat).
- arylalkyloxycarbonyl represents an "arylalkyloxy” group as defined above attached through a carbonyl group (e.g., benzylformiat and phenyletylformiat).
- alkylthio represents an alkyl group having the indicated number of carbon atoms attached through a sulphur bridge (e.g., methylthio and ethylthio).
- arylthio represents an aryl group as defined above attached through a sulphur bridge (e.g., benzenthiol and naphthylthiol).
- hetarylthio represents a hetaryl group as defined above attached through a sulphur bridge (e.g., pyridine-2-thiol and thiazole-2-thiol).
- arylthioalkyl represents an arylthio group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., methylsulfanyl benzene, and ethylsulfanyl naphthalene).
- hetarylthioalkyl represents a hetarylthio group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 2-methylsulfanyl- pyridine and 1 -ethylsulfanyl-isoquinoline).
- hetaryloxyaryl represents a hetaryloxy group as defined above attached through an aryl group as defined above (e.g., 1 -phenoxy-isoquinolyl and 2-phenoxypyridyl).
- hetaryloxyhetaryl represents a hetaryloxy group as defined above attached through a hetaryl group as defined above (e.g., 1 -(2-pyridyloxy-isoquinoline) and 2- (imidazol-2-yloxy-pyridine)).
- aryloxyalkyl represents an aryloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., phenoxymethyl and naphthyloxyethyl).
- aryloxyaryl represents an aryloxy group as defined above attached through an aryl group as defined above (e.g., 1 -phenoxy-naphthalene and phenyloxy- phenyl).
- arylalkyloxyalkyl represents an arylalkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., ethoxy- methyl-benzene and 2-methoxymethyl-naphthalene).
- hetaryloxyalkyl represents a hetaryloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 2- pyridyloxymethyl and 2-quinolyloxyethyl).
- hetarylalkyloxyalkyl represents a hetarylalkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., A- methoxymethyl-pyrimidine and 2-methoxymethyl-quinoline).
- alkylcarbonyl represents an alkyl group as defined above having the indi- cated number of carbon atoms attached through a carbonyl group (e.g., octylcarbonyl, pen- tylcarbonyl, and 3-hexenylcarbonyl).
- arylcarbonyl represents an aryl group as defined above attached through a carbonyl group (e.g., benzoyl).
- hetarylcarbonyl represents a hetaryl group as defined above attached through a carbonyl group (e.g., 2-thiophenylcarbonyl, 3-methoxy-anthrylcarbonyl, and oxa- zolylcarbonyl).
- carbonylalkyl represents a carbonyl group attached through an alkyl group having the indicated number of carbon atoms (e.g., acetyl).
- alkylcarbonylalkyl represents an alkylcarbonyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., propan-
- arylcarbonylalkyl represents a arylcarbonyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 1 -phenyl- propan-1 -one and 1 -(3-chloro-phenyl)-2-methyl-butan-1 -one).
- hetarylcarbonylalkyl represents a hetarylcarbonyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 1 - pyridin-2-yl-propan-1 -one and 1 -(1 -H-imidazol-2-yl)-propan-1 -one).
- arylalkylcarbonyl represents an arylalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., phenylpro- pylcarbonyl and phenylethylcarbonyl).
- hetarylalkylcarbonyl represents a hetarylalkyl group as defined above wherein the alkyl group is in turn attached through a carbonyl (e.g., imidazolylpentylcar- bonyl).
- alkylcarbonylamino represents an “alkylcarbonyl” group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group (e.g., methylcarbonylamino, cyclopentylcarbonyl-aminomethyl, and methylcarbonylaminophenyl).
- the nitrogen atom may itself be substituted with an alkyl or aryl group.
- alkylcarbonylaminoalkyl represents an "alkylcarbonylamino” group attached through an alkyl group having the indicated number of carbon atoms (e.g.N-propyl- acetamide and N-butyl-propionamide).
- arylalkylcarbonylamino represents an "arylalkylcarbonyl” group as defined above attached through an amino group (e.g., phenylacetamide and 3-phenyl- propionamide).
- arylalkylcarbonylaminoalkyl represents an “arylalkylcarbonylamino” group attached through an alkyl group having the indicated number of carbon atoms (e.g., N-ethyl- phenylacetamide and N-butyl-3-phenyl-propionamide).
- arylcarbonylamino represents an "arylcarbonyl” group as defined above attached through an amino group (e.g., benzamide and naphthalene-1 -carboxylic acid amide).
- arylcarbonylaminoalkyl represents an "arylcarbonylamino” group attached through an alkyl group having the indicated number of carbon atoms (e.g., N-propyl- benzamide and N-Butyl-naphthalene-1 -carboxylic acid amide).
- alkylcarboxy represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., heptylcarboxy, cyclopropyl- carboxy, and 3-pentenylcarboxy).
- arylcarboxy represents an arylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., benzoic acid).
- alkylcarboxyalkyl represents an alkylcarboxy group as defined above wherein the oxygen is attached via an alkyl bridge (e.g., heptylcarboxymethyl, propylcarboxy te/t-butyl, and 3-pentylcarboxyethyl).
- arylalkylcarboxy represents an arylalkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., benzylcarboxy and phenylpropylcarboxy).
- arylalkylcarboxyalkyl represents an arylalkylcarboxy group as defined above wherein the carboxy group is in turn attached through an alkyl group having the indicated number of carbon atoms (e.g., benzylcarboxymethyl and phenylpropylcarboxypropyl).
- hetarylcarboxy represents a hetarylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., pyridine-2- carboxylic acid).
- hetarylalkylcarboxy represents a hetarylalkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., (1 -H- imidazol-2-yl)-acetic acid and 3-pyrimidin-2-yl-propionic acid).
- an oxygen bridge e.g., (1 -H- imidazol-2-yl)-acetic acid and 3-pyrimidin-2-yl-propionic acid.
- alkylSO m represents an alkyl group having the number of indicated carbon atoms, wherein the alkyl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms (e.g., ethylsulfonyl and ethylsulfinyl).
- arylSO m represents an aryl group as defined above, wherein the aryl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms (e.g., phenylsulfinyl and naphthyl-2-sulfonyl).
- hetarylSO m represents a hetaryl group as defined above, wherein the hetaryl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms (e.g., thiazol-2-sulfinyl and pyridine-2-sulfonyl).
- m oxygen atoms e.g., thiazol-2-sulfinyl and pyridine-2-sulfonyl.
- treatment is defined as the management and care of a patient for the purpose of combating or alleviating the disease, condition, or disorder, and the term includes the administration of the active compound to prevent or delay the onset of the symptoms or complications; alleviating (both temporary and permanent) the symptoms or complications; and/or eliminating the disease, condition, or disorder.
- treatment includes prevention and/or prophylaxis of the disease, condition, or disorder.
- pharmaceutically acceptable is defined as being suitable for administra- tion to humans without adverse events.
- prodrug is defined as a chemically modified form of the active drug, said prodrug being administered to the patient and subsequently being converted to the active drug. Techniques for development of prodrugs are well known in the art.
- the present invention provides for the novel use of a substituted amide, a prodrug thereof, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any tautomeric forms, wherein the substituted amide or a prodrug thereof is of formula I:
- X is selected from CR 5 and nitrogen;
- R 1 is selected from H and d-C 6 alkyl-R 6 , wherein the alkyl group is substituted with 0- 3 R 7 ;
- R and R are, independently, R a R ⁇
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulphur;
- Ring A is substituted with 0-3 groups selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, d-C 6 alkyloxy, Ci-CealkyloxyCi-Cealkylene, and d-C 6 alkylcarbonyl, wherein each alkyl/alkylene group is substituted with 0-3 R 14 ;
- R 7 is selected from halo, hydroxy, oxo, cyano, and d-C 8 alkyl
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen, d-C 8 alkyl, F, trihalomethyl, trihalomethoxy, hydroxy, and d-C 6 alkyloxy, wherein the d-C 8 alkyl and d- C 6 alkyloxy are substituted with 0-3 R 17 ;
- R 8 and R 9 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryloxy, aryl
- R 10 and R 11 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, CrC 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryloxy, arylCrC 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 8 and R 10 together with the two carbon atoms to which they are attached form a saturated or partially saturated ring consisting of the two shown carbon atoms, 1 -4 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, d- C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy, and hetarylCi-C 6 alkyloxy;
- R 13 is selected from OH, d-C 8 alkyl, d-C 8 alkyloxy, d-dalkyloxyd-dalkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
- R 14 is selected from halo, hydroxy, oxo, and cyano;
- R 18 and R 19 are independently selected from H, C r C 8 alkyl, C r C 8 alkyloxy, aryl, hetaryl, arylCi-C 6 alkylene, and hetarylCi-C 6 alkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-3 R 20 ;
- R 18 and R 19 together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulfur, wherein this ring is substituted with 0-3 Ci-C 8 alkyl, aryl, hetaryl, arylCrC 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, d-Cealkyloxyd-Cealkyl, d-C 6 alkylcarbonyl, arylcarbonyl, hetarylcar- bonyl, aryld-Cealkylcarbonyl, hetaryld-Cealkylcarbonyl, hetaryld-C
- R 20 is selected from H, OH, oxo, halo, cyano, nitro, d-C 6 alkyl, d-C 6 alkyloxy, NR 21 R 22 , methylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
- R 21 and R 22 are independently selected from H, C r C 8 alkyl, and arylCi-C 6 alkyl;
- R 23 is selected from H and d-C 6 alkyl
- n is selected from 0, 1 , and 2;
- Y is selected from O and S;
- the present invention provides the novel use of compounds of formula I, wherein: [00116] R 1 is selected from H and Ci-C 4 alkyl-R 6 , wherein the alkyl group is substituted with 0-1 R 7 ;
- R 1 and R 2 are, independently, R R ;
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen and 7-10 carbon atoms;
- Ring A is substituted with 0-3 groups selected from d-C 4 alkyl, halo, hydroxy, and CrC 6 alkyloxy;
- R 5 is selected from hydrogen and d-C 4 alkyl
- R 7 is selected from halo and C r C 4 alkyl
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen and d-C 4 alkyl;
- R 8 and R 10 together with the two carbon atoms to which they are attached form a saturated or partially saturated ring consisting of the two shown carbon atoms and 1 -4 additional carbon atoms, wherein this ring is substituted with 0-1 groups selected from halo, trihalomethyl, hydroxyl, and d-C 6 alkyl;
- R 12 is selected from H, OH, and NR 18 R 19 ;
- R 13 is selected from OH, Ci-C 4 alkyl, Ci-C 4 alkyloxy, Ci-C 4 alkyloxyCi-C 4 alkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
- R 18 and R 19 are independently selected from H, C r C 4 alkyl, C r C 4 alkyloxy, aryl, hetaryl, arylCi-C 4 alkylene, and hetarylCi-C 4 alkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-1 R 20 ;
- R 18 and R 19 together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from ni- trogen, oxygen, and sulfur, wherein this ring is substituted with 0-1 C r C 4 alkyl, aryl, hetaryl, arylCrC 4 alkylene, hetarylCi-C 4 alkylene, hydroxy, and Ci-C 4 alkyloxy;
- R 20 is selected from H, OH, oxo, halo, cyano, nitro, C r C 4 alkyl, C r C 4 alkyloxy, NR 21 R 22 , trihalomethyl, and trihalomethyloxy;
- R 21 and R 22 are independently selected from H, C r C 4 alkyl, and arylC r C 4 alkyl;
- R 23 is selected from H and d-C 6 alkyl
- n is selected from 0, 1 , and 2;
- Y is selected from O and S.
- the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula IA:
- the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula IB:
- the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula IC:
- the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula ID:
- Ring A is selected from:
- Ring A is substituted with 0-2 R ⁇ 4 ;
- R is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and Ci-C 6 alkyloxy.
- Ring A is [00146] [9]
- the present invention provides the novel use of compounds of formula I, wherein the substituted amide or a prodrug thereof is of the selected from the group:
- the present invention provides for the novel preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial.
- the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
- the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the pharmaceutical composition is suitable for a route of administration selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
- the present invention provides a novel method for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound of the present invention.
- the present invention provides a novel method wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
- the present invention provides a novel method wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the present invention provides a novel method wherein the administering is via a route selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
- the present invention provides for a novel compound of of formula I:
- X is selected from CR 5 and nitrogen;
- R 1 is selected from H and d-C 6 alkyl-R 6 , wherein the alkyl group is substituted with 0-3 R 7 ;
- R 1 and R 2 are, independently, R R
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulphur;
- Ring A is substituted with 0-3 groups selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, Ci-C 6 alkyloxy, Ci-CealkyloxyCi-Cealkylene, and Ci-C 6 alkylcarbonyl, wherein each alkyl/alkylene group is substituted with 0-3 R 14 ;
- R 7 is selected from halo, hydroxy, oxo, cyano, and d-C 8 alkyl
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen, d-C 8 alkyl, F, trihalomethyl, trihalomethoxy, hydroxy, and Ci-C 6 alkyloxy, wherein the Ci-C 8 alkyl and d- C 6 alkyloxy are substituted with 0-3 R 17 ;
- R 8 and R 9 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 10 and R 11 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, CrC 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 13 is selected from OH, d-C 8 alkyl, d-C 8 alkyloxy, Ci-C 8 alkyloxyCi-C 4 alkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
- R 14 is selected from halo, hydroxy, oxo, and cyano;
- R 18 and R 19 are independently selected from H, C r C 8 alkyl, C r C 8 alkyloxy, aryl, hetaryl, arylCi-C 6 alkylene, and hetarylCi-C 6 alkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-3 R 20 ;
- R 18 and R 19 together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulfur, wherein this ring is substituted with 0-3 Ci-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C 6 alkylcarbonyl, arylcarbonyl, hetarylcar- bonyl, arylCi-C 6 alkylcarbonyl, hetarylCi-Cealkyl
- R 20 is selected from H, OH, oxo, halo, cyano, nitro, d-C 6 alkyl, d-C 6 alkyloxy, NR 21 R 22 , methylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
- R 21 and R 22 are independently selected from H, C r C 8 alkyl, and arylCi-C 6 alkyl;
- R 23 is selected from H and d-C 6 alkyl; [00181] n is selected from 0, 1 , and 2;
- Y is selected from O and S;
- the present invention provides the novel compound of formula I, wherein:
- R 1 is selected from H and Ci-C 4 alkyl-R 6 , wherein the alkyl group is substituted with 0-1 R 7 ;
- R 1 and R 2 are, independently, R" R
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen and 7-10 carbon atoms;
- Ring A is substituted with 0-3 groups selected from d-C 4 alkyl, halo, hydroxy, and Ci-C 6 alkyloxy;
- R 5 is selected from hydrogen and d-C 4 alkyl
- R 7 is selected from halo and d-C 4 alkyl;
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen and C r C 4 alkyl;
- R 8 and R 10 together with the two carbon atoms to which they are at- tached form a saturated or partially saturated ring consisting of the two shown carbon atoms and 1 -4 additional carbon atoms, wherein this ring is substituted with 0-1 groups selected from halo, trihalomethyl, hydroxyl, and Ci-C 6 alkyl;
- R 12 is selected from H, OH, and NR 18 R 19 ;
- R 13 is selected from OH, d-C 4 alkyl, d-C 4 alkyloxy, d-dalkyloxyd-dalkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
- R 18 and R 19 are independently selected from H, d-C 4 alkyl, d-C 4 alkyloxy, aryl, hetaryl, aryld-C 4 alkylene, and hetaryld-dalkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-1 R 20 ;
- R 18 and R 19 together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from ni- trogen, oxygen, and sulfur, wherein this ring is substituted with 0-1 d-C 4 alkyl, aryl, hetaryl, arylCrdalkylene, hetarylCi-C 4 alkylene, hydroxy, and Ci-C 4 alkyloxy;
- R 20 is selected from H, OH, oxo, halo, cyano, nitro, d-C 4 alkyl, d-C 4 alkyloxy, NR 21 R 22 , trihalomethyl, and trihalomethyloxy;
- R 21 and R 22 are independently selected from H, C r C 4 alkyl, and arylC r C 4 alkyl;
- R 23 is selected from H and d-C 6 alkyl
- n is selected from 0, 1 , and 2; and, [00204] Y is selected from O and S.
- the present invention provides the novel compounds of formula IB:
- the present invention provides the novel compounds of formula IC:
- the present invention provides the novel compounds of formula I, wherein:
- Ring A is selected from:
- Ring A is substituted with 0-2 R ⁇ 4 ;
- R is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and Ci-C 6 alkyloxy.
- Ring A is [00215] [26]
- the present invention provides the novel compounds of formula I, selected from the group:
- the present invention provides for a novel compound of of formula I:
- X is selected from CR 5 and nitrogen
- R 1 is selected from CrC 6 alkyl-R 6 , wherein the alkyl group is substituted with 0-3 R 7 ;
- R 1 and R 2 are, independently, R" R- ⁇ 11
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulphur;
- Rx is selected from hydrogen and d-C 6 alkyl
- R 7 is selected from d-C 6 alkyl, halo, hydroxy, oxo and cyano;
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen, d-C 8 alkyl, F, triha- lomethyl, trihalomethoxy, hydroxy, and d-C 6 alkyloxy, wherein the d-C 8 alkyl and d- C 6 alkyloxy are substituted with 0-3 R 17 ;
- R 8 and R 9 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 10 and R 11 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 8 and R 10 together with the two carbon atoms to which they are attached form a saturated or partially saturated ring consisting of the two shown carbon atoms, 1 -4 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy, and hetarylCi-C 6 alkyloxy;
- R 13 is selected from OH, d-C 8 alkyl, d-C 8 alkyloxy, Ci-C 8 alkyloxyCi-C 4 alkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
- R 14 is selected from halo, hydroxy, oxo, and cyano
- R 18 and R 19 are independently selected from H, C r C 8 alkyl, Ci-C 8 alkyloxy, aryl, hetaryl, arylCi-C 6 alkylene, and hetarylCi-C 6 alkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-3 R 20 ;
- R 18 and R 19 together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulfur, wherein this ring is substituted with 0-3 Ci-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryld- C 6 alkyloxy, hetarylCi-C 6 alkyloxy, d-Cealkyloxyd-Cealkyl, d-C 6 alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, arylCi-C 6 alkylcarbonyl, hetarylCi-C 6 alkylcarbonyl, d-C 6 al
- R 21 and R 22 are independently selected from H, CrC 8 alkyl, and arylCrC 6 alkyl;
- R 23 is selected from H and d-C 6 alkyl
- n is selected from O, 1 , and 2;
- Y is selected from O and S;
- any optical isomer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
- the present invention provides for a novel compound of of formula I:
- X is selected from CR 5 and nitrogen
- R 1 is selected from d-C 6 alkyl-R 6 , wherein the alkyl group is substituted with 0-3 R 7.
- R 1 and R 2 are, independently, R 3 R Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulphur;
- Rx is selected from hydrogen and CrC 6 alkyl
- R 7 is selected from d-C 6 alkyl, halo, hydroxy, oxo and cyano;
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen, Ci-C 8 alkyl, F, triha- lomethyl, trihalomethoxy, hydroxy, and d-C 6 alkyloxy, wherein the d-C 8 alkyl and d- C 6 alkyloxy are substituted with 0-3 R 17 ; alternatively, R 8 and R 9 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alky
- R 10 and R 11 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 addi- tional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, CrC 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 8 and R 10 together with the two carbon atoms to which they are attached form a saturated or partially saturated ring consisting of the two shown carbon atoms, 1 -4 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy, and hetarylCi-C 6 alkyloxy;
- R 13 is selected from OH, d-C 8 alkyl, d-C 8 alkyloxy, d-C 8 alkyloxyd-C 4 alkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
- R 14 is selected from halo, hydroxy, oxo, and cyano
- R 18 and R 19 are independently selected from H, d-C 8 alkyl, d-C 8 alkyloxy, aryl, hetaryl, arylCrC 6 alkylene, and hetarylCrC 6 alkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-3 R 20 ;
- R 18 and R 19 together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from ni- trogen, oxygen, and sulfur, wherein this ring is substituted with 0-3 d-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryld- C 6 alkyloxy, hetarylCi-C 6 alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C 6 alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, arylCi-C 6 alkylcarbonyl, hetarylCi-Cealkyl
- R 20 is selected from H, OH, oxo, halo, cyano, nitro, d-C 6 alkyl, d-C 6 alkyloxy, NR 21 R 22 , me- thylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
- R 21 and R 22 are independently selected from H, d-C 8 alkyl, and arylCi-C 6 alkyl;
- R 23 is selected from H and d-C 6 alkyl
- n is selected from 0, 1 , and 2;
- Y is selected from O and S;
- any optical isomer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
- the present invention provides for a novel compound of of formula I, wherein: X is selected from CR 5 and nitrogen;
- R 1 is selected from d-C 6 alkyl-R 6 , wherein the alkyl group is substituted with 0-3 R 7 ;
- R 1 and R 2 are, independently, R" R11
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and sulphur;
- Rx is selected from hydrogen and d-C 6 alkyl
- R 7 is selected from halo, hydroxy, oxo and cyano
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen, d-C 8 alkyl, F, triha- lomethyl, trihalomethoxy, hydroxy, and d-C 6 alkyloxy, wherein the d-C 8 alkyl and d- C 6 alkyloxy are substituted with 0-3 R 17 ;
- R 8 and R 9 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 10 and R 11 together with the carbon atom to which they are attached form a saturated or partially saturated ring consisting of the carbon atom shown, 2-5 addi- tional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, Ci-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy or hetarylCi-C 6 alkyloxy;
- R 8 and R 10 together with the two carbon atoms to which they are attached form a saturated or partially saturated ring consisting of the two shown carbon atoms, 1 -4 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein this ring is substituted with 0-3 groups selected from halo, triha- lomethyl, d-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryloxy, arylCi-C 6 alkyloxy, and hetarylCi-C 6 alkyloxy;
- R 14 is selected from halo, hydroxy, oxo, and cyano
- R 18 and R 19 are independently selected from H, C r C 8 alkyl, Ci-C 8 alkyloxy, aryl, hetaryl, arylCi-C 6 alkylene, and hetarylCi-C 6 alkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-3 R 20 ;
- R 18 and R 19 together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from ni- trogen, oxygen, and sulfur, wherein this ring is substituted with 0-3 Ci-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, d-C 6 alkyloxy, aryld- C 6 alkyloxy, hetarylCi-C 6 alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C 6 alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, arylCi-C 6 alkylcarbonyl, hetarylCi-Cealkylcarbon
- R 20 is selected from H, OH, oxo, halo, cyano, nitro, d-C 6 alkyl, d-C 6 alkyloxy, NR 21 R 22 , me- thylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
- R 21 and R 22 are independently selected from H, C r C 8 alkyl, and arylCi-C 6 alkyl;
- R 23 is selected from H and d-C 6 alkyl
- n is selected from 0, 1 , and 2; Y is selected from O and S;
- any optical isomer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
- the present invention provides for a novel compound of of formula I, wherein
- R 1 is Ci-C 4 alkyl-R 6 , wherein the alkyl group is substituted with 0-1 R 7 ;
- R and R are, independently, R 3 R 1
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen and 7-10 carbon atoms;
- Rx is selected from hydrogen and CrC 6 alkyl
- R 5 is selected from hydrogen and Ci-C 4 alkyl
- R 7 is selected from halo
- R 8 , R 9 , R 10 and R 11 are each independently selected from hydrogen and d-C 4 alkyl;
- R 8 and R 10 together with the two carbon atoms to which they are attached form a saturated or partially saturated ring consisting of the two shown carbon atoms and 1 -4 additional carbon atoms, wherein this ring is substituted with 0-1 groups selected from halo, trihalomethyl, hydroxyl, and d-C 6 alkyl;
- R 12 is selected from H, OH, and NR 18 R 19 ;
- R 13 is selected from OH, d-C 4 alkyl, d-C 4 alkyloxy, Ci-C 4 alkyloxyCi-C 4 alkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
- R 18 and R 19 are independently selected from H, Ci-C 4 alkyl, Ci-C 4 alkyloxy, aryl, hetaryl, arylCi-C 4 alkylene, and hetarylCi-C 4 alkylene, wherein the alkyl/alkylene, aryl, and hetaryl groups are independently substituted with 0-1 R 20 ; alternatively, R 18 and R 19 , together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxygen, and sulfur, wherein this ring is substituted with 0-1 CrC 4 alkyl, aryl, hetaryl, arylCi-C 4 alkylene, hetarylCi-C 4 alkylene, hydroxy, and Ci-C 4 alkyloxy;
- R 20 is selected from H, OH, oxo, halo, cyano, nitro, C r C 4 alkyl, C r C 4 alkyloxy, NR 21 R 22 , triha- lomethyl, and trihalomethyloxy;
- R 21 and R 22 are independently selected from H, C r C 4 alkyl, and arylCi-C 4 alkyl;
- R 23 is selected from H and d-C 6 alkyl
- n is selected from 0, 1 , and 2;
- Y is selected from O and S;
- any optical isomer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
- the present invention provides for a novel compound of of formula IA:
- the present invention provides for a novel compound of of formula IB:
- the present invention provides for a novel compound of of formula IC:
- the present invention provides for a novel compound of of formula ID:
- the present invention provides for a novel compound of of formula I, wherein R 7 is Ci-C 6 alkyl.
- the present invention provides for a novel compound of of formula I, wherein R 7 is halo.
- the present invention provides for a novel compound of of formula I, wherein R 7 is hydroxy.
- the present invention provides for a novel compound of of formula I, wherein R 7 is oxo.
- the present invention provides for a novel compound of of formula I, wherein R 7 is cyano.
- the present invention provides for a novel compound of of formula I, wherein Y is oxygen (O).
- the present invention provides for a novel compound of of formula I, wherein
- the present invention provides for a novel compound of of formula I, wherein
- Ring A is a saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 1 -2 additional heteroatoms selected from nitrogen, oxygen, and sulphur;
- the present invention provides for a novel compound of of formula I, wherein Ring A is selected from:
- the present invention provides for a novel compound of of formula I, wherein Ring A is
- the present invention provides for a novel compound of of formula I wherein Ring A is
- the present invention provides for a novel compound of of formula I, wherein Ring A is
- the present invention provides for a novel compound of of formula I, wherein Ring A is
- the present invention provides for a novel compound of of formula I, wherein Ring A is
- the present invention provides for a novel compound of of formula I, wherein Ring A is
- the present invention provides for a novel compound of of formula I, wherein
- Rx is selected from hydrogen and CrC 6 alkyl
- the present invention provides for a novel compound of of formula I, wherein
- Rx is selected from hydrogen and d-C 6 alkyl
- the present invention provides for a novel compound, wherein the compound is of the selected from the group: Furan-2-carboxylic acid ⁇ 2-[5-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzoimidazol-1 -yl]-ethyl ⁇ -amide i -Acetyl-piperidine ⁇ -carboxylic acid ⁇ 2-[5-(1 ⁇ S-trimethyl- ⁇ -aza-bicyclo ⁇ .i Joctane- ⁇ - carbonyl)-benzoimidazol-1 -yl]-ethyl ⁇ -amide
- the present invention provides for a use of a compound of of formula I, for the preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial.
- the present invention provides for a use of a compound of of formula I for the preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases, wherein the conditions, disorders, and diseases are influenced by intracellular glucocorticoid levels.
- the present invention provides for a use of a compound of of formula I for the preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases, wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the present invention provides for a method for the treat- ment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound of formula I.
- the present invention provides for a method for the treat- ment of conditions, disorders or diseases, wherein the conditions, disorders, and diseases are influenced by intracellular glucocorticoid levels, the method comprising administering to a subject in need thereof an effective amount of a compound of formula I.
- the present invention provides for a method for the treat- ment of conditions, disorders or diseases, wherein the conditions, disorders or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the conditions, disorders or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the present invention provides a novel compound, which is an agent useful for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial.
- the present invention provides a novel method wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
- the present invention provides a novel method wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- the present invention provides a novel method phar- maceutical composition
- a novel method phar- maceutical composition comprising, as an active ingredient, at least one compound according of the present invention together with one or more pharmaceutically acceptable carriers or excipients.
- the present invention provides a novel pharmaceutical composition, which is suitable for oral, nasal, buccal, transdermal, pulmonal, or parenteral administration.
- the compounds of the present invention may have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms being included in the present invention as well as mixtures thereof.
- the present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
- Acid addition salts include salts of inorganic ac- ids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, and nitric acids.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hy- droxynaphthoates,
- compositions include the pharmaceutically acceptable salts listed in J. Pharm. ScL, 66, 2 (1977), which is incorporated herein by reference.
- metal salts include lithium, sodium, potassium, barium, calcium, magnesium, zinc, and calcium salts.
- amines and organic amines include ammonium, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, propylamine, bu- tylamine, tetramethylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, choline, N,N'-dibenzylethylenediamine, N-benzylphenylethylamine, N- methyl-D-glucamine, and guanidine.
- cationic amino acids include lysine, argin- ine, and histidine.
- solvates may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.
- the pharmaceutically acceptable salts are prepared by reacting a compound of the present invention with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium te/t-butoxide, calcium hydroxide, and magnesium hydroxide, in solvents such as ether, THF, methanol, te/t-butanol, dioxane, and isopropanol, ethanol. Mixtures of solvents may be used.
- Organic bases such as lysine, arginine, dietha- nolamine, choline, guandine and their derivatives etc. may also be used.
- acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, and tartaric acid in solvents such as ethyl acetate, ether, alcohols, acetone, THF, and dioxane. Mixture of solvents may also be used.
- acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid
- the stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enanti- omer form or by resolving the mixture of stereoisomers by conventional methods.
- Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, and lactic acid, wherever applicable or chiral bases such as brucine, (R)- or (S)-phenylethylamine, cinchona alkaloids and their derivatives.
- the compound of the present invention may be converted to a 1 :1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, ami- noalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydrolysing the pure diastereomeric amide.
- polymorphs of the compounds forming part of this invention may be prepared by crystallization of said compounds under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at dif- ferent temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
- the invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
- prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the present invention.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
- the Original compound' it is within the scope of the invention to modify the compounds of the present invention, termed the Original compound', by attaching chemical groups that will improve the bioavailability of said compounds in such a way that the uptake in cells or mammals is facilitated.
- Examples of said modifications which are not intended in any way to limit the scope of the invention, include changing of one or more carboxy groups to esters (for instance methyl esters, ethyl esters, te/t-butyl, acetoxymethyl, pivaloyloxymethyl esters or other acyloxymethyl esters).
- esters for instance methyl esters, ethyl esters, te/t-butyl, acetoxymethyl, pivaloyloxymethyl esters or other acyloxymethyl esters.
- Compounds of the invention, original compounds, such modified by attaching chemical groups are termed 'modified compounds'.
- the invention also encompasses active metabolites of the present compounds.
- the compounds according to the invention alter, and more specifically, reduce the level of active intracellular glucocorticoid and are accordingly useful for the treatment of conditions, disorders, and diseases in which such a modulation or reduction is beneficial.
- the present compounds may be applicable for the treatment of the metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), Latent Autoimmune Diabetes in the Adult (LADA), type 1 diabetes, diabetic late complications including cardiovascular diseases, cardiovascular disorders, disorders of lipid metabolism, neurodegenerative and psychiatric disorders, dysregulation of intraocular pressure including glaucoma, immune dis- orders, inappropriate immune responses, musculoskeletal disorders, gastrointestinal disorders, polycystic ovarie syndrome (PCOS), reduced hair growth or other diseases, disorders or conditions that are influenced by intracellular glucocorticoid levels, adverse effects of increased blood levels of active endogenous or exogenous glucocorticoid, and any combination thereof, adverse effects of increased plasma levels of endogenous active glucocorticoid, Cushing's disease, Cushing's syndrome, adverse effects of glucocorticoid receptor agonist treatment of autoimmune diseases, adverse
- the present compounds may be applicable for the treatment of the metabolic syndrome, type 2 diabetes, diabetes as a consequence of obesity, insulin resistance, hyperglycemia, prandial hyperglycemia, hyperinsulinemia, inappropriately low insulin secretion, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), increased he- patic glucose production, type 1 diabetes, LADA, pediatric diabetes, dyslipidemia, diabetic dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, decreased HDL cholesterol, impaired LDL/HDL ratio, other disorders of lipid metabolism, obesity, visceral obesity, obesity as a consequence of diabetes, increased food intake, hypertension, diabetic late complications, micro-/macroalbuminuria, nephropathy, retinopathy, neuropathy, diabetic ulcers, cardiovascular diseases, arteriosclerosis, atherosclerosis, coronary artery disease, cardiac hypertrophy, myocardial ischemia, heart insufficiency, congestional heart failure, stroke,
- the invention relates to a compound according to the invention for use as a pharmaceutical composition.
- the invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound according to the invention together with one or more pharmaceutically acceptable carriers or diluents.
- the pharmaceutical composition is preferably in unit dosage form, comprising from about 0.05 mg/day to about 2000 mg/day, preferably from about 0.1 mg/day to abouti OOO mg/day, and more preferably from about 0.5 mg/day to about 500 mg/day of a compound according to the invention.
- the patient is treated with a compound according to the invention for at least about 1 week, for at least about 2 weeks, for at least about 4 weeks, for at least about 2 months or for at least about 4 months.
- the pharmaceutical composition is for oral, nasal, buccal, transdermal, pulmonal or parenteral administration.
- the invention relates to the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment of disorders and diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial.
- the invention also relates to a method for the treatment of disorders and diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to the invention.
- the present compounds are used for the preparation of a medicament for the treatment of any diseases and conditions that are influenced by intracellular glucocorticoid levels as mentioned above.
- the present compounds are used for the preparation of a medicament for the treatment of conditions and disorders where a decreased level of active intracellular glucocorticoid is desirable, such as the conditions and diseases mentioned above.
- the present compounds are used for the preparation of a medicament for the treatment of metabolic syndrome, insulin resistance, dyslipidemia, hypertension obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of the metabolic syndrome into type 2 diabetes, diabetic late complications (e.g., cardiovascular diseases, arteriosclerosis, and atherosclerosis), neurodegenerative and psychiatric disorders, and, the adverse effects of glucocorticoid receptor agonist treatment or therapy.
- IGT impaired glucose tolerance
- IGF impaired fasting glucose
- the route of administration may be any route which effectively transports a compound according to the invention to the appropriate or desired site of action, such as oral, nasal, buccal, transdermal, pulmonal, or parenteral.
- the present compounds are administered in combination with one or more further active substances in any suitable ratios.
- Such further active substances may e.g., be selected from antiobesity agents, antidiabetics, agents modi- fying the lipid metabolism, antihypertensive agents, glucocorticoid receptor agonists, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
- the present compounds may be adminis- tered in combination with one or more antiobesity agents or appetite regulating agents.
- Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melano- cortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) an- tagonists, urocortin agonists, ⁇ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists
- TNF
- the antiobesity agent is leptin; dexamphetamine or amphetamine; fenfluramine or dexfenfluramine; sibutramine; orlistat; mazindol or phen- termine.
- Suitable antidiabetic agents include insulin, insulin analogues and derivatives such as those disclosed in EP 792 290 (Novo Nordisk A/S), e.g., N ⁇ B29 -tetradecanoyl des (B30) human insulin, EP 214 826 and EP 705 275 (Novo Nordisk A/S), e.g., Asp B28 human insulin, US 5,504,188 (EIi Lilly), e.g., Lys B28 Pro 629 human insulin, EP 368 187 (Aventis), eg Lantus, which are all incorporated herein by reference, GLP-1 (glucagon like peptide-1 ) and GLP-1 derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents.
- EP 792 290 Novo Nordisk A/S
- N ⁇ B29 -tetradecanoyl des B30 human insulin
- the orally active hypoglycaemic agents preferably comprise sulphonylureas, bigua- nides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase- IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenosis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as PPAR ⁇ modulators, PPAR ⁇ modulators, cholesterol absorption inhibitors, HSL (hormone-sensitive lipase) inhibitors and HMG CoA inhibitors
- the present compounds are administered in combination with insulin or an insulin analogue or derivative, such as N ⁇ B29 -tetradecanoyl des (B30) human insulin, Asp B28 human insulin, Lys B28 Pro 629 human insulin, Lantus®, or a mix-preparation comprising one or more of these.
- insulin an insulin analogue or derivative, such as N ⁇ B29 -tetradecanoyl des (B30) human insulin, Asp B28 human insulin, Lys B28 Pro 629 human insulin, Lantus®, or a mix-preparation comprising one or more of these.
- the present compounds are administered in combination with a sulphonylurea e.g., tolbutamide, glibenclamide, glipizide or glicazide.
- a sulphonylurea e.g., tolbutamide, glibenclamide, glipizide or glicazide.
- the present compounds are administered in combination with a biguanide e.g., metformin.
- the present compounds are administered in combination with a meglitinide e.g., repaglinide or senaglinide.
- the present compounds are administered in combination with a thiazolidinedione e.g., troglitazone, ciglitazone, pioglitazone, rosiglitazone or compounds disclosed in WO 97/41097 such as 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazo- linyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof, preferably the potassium salt.
- a thiazolidinedione e.g., troglitazone, ciglitazone, pioglitazone, rosiglitazone or compounds disclosed in WO 97/41097 such as 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazo- linyl]methoxy]phenyl-methyl]thiazolidine-2,4-di
- the present compounds may be administered in combination with the insulin sensitizers disclosed in WO 99/19313 such as (-) 3-[4-[2-Phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid or a pharmaceutically acceptable salts thereof, preferably the arginine salt.
- the present compounds are administered in combination with an ⁇ -glucosidase inhibitor e.g., miglitol or acarbose.
- an agent acting on the ATP-dependent potassium channel of the ⁇ -cells e.g., tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
- the present compounds may be administered in combination with nateglinide.
- the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent e.g., cholestyramine, colestipol, clofibrate, gemfibrozil, fenofibrate, bezafibrate, tesaglitazar, EML-4156, LY-818, MK-767, atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, acipimox, probucol, ezetimibe or dextrothyroxine.
- an antihyperlipidemic agent or antilipidemic agent e.g., cholestyramine, colestipol, clofibrate, gemfibrozil, fenofibrate, bezafibrate, tesaglitazar, EML-4156, LY-818, MK-767, atorvastatin, fluvastat
- the present compounds are administered in combination with more than one of the above-mentioned compounds e.g., in combination with a sulphon- ylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
- the present compounds may be administered in combination with one or more antihypertensive agents.
- antihypertensive agents are ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol, metoprolol, bisoprololfumerate, esmolol, acebutelol, metoprolol, acebutolol, betaxolol, celiprolol, nebivolol, tertatolol, oxprenolol, amusolalul, carvedilol, labetalol, ⁇ 2-receptor blockers e.g., S-atenolol, OPC- 1085, ACE (angiotensin converting enzyme) inhibitors such as quinapril, lisinopril, enalapril, captopril, benazepril, perindopril, trandolapril, fosinopril
- the present compounds may be administered in combination with one or more glucocorticoid receptor agonists.
- glucocorticoid receptor agonists examples include betametasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, beclomethasone, butixicort, clobetasol, flunisolide, flucatisone (and analogues), momethasone, triamcinolonacetonide, triamcinolonhexacetonide GW-685698, NXC-1015, NXC-1020, NXC-1021 , NS-126, P-41 12, P-41 14, RU-24858 and T-25 series.
- any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
- the compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
- the pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy,19 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
- compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
- Pharmaceutical compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, troches, dragees, pills, lozenges, powders and granules.
- Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
- compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.
- a typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages.
- the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
- a typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.05 to about 2000 mg, e.g., from about 0.1 to about 1000 mg, from about 0.5 mg to about 500 mg., from about 1 mg to about 200 mg, e.g., about 100 mg.
- typically doses are in the order of about half the dose employed for oral administration.
- the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
- examples are an acid addition salt of a compound having the utility of a free base and a base addition salt of a compound having the utility of a free acid.
- pharmaceutically acceptable salts refers to non-toxic salts of the compounds for use according to the present invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the acid with a suitable organic or inorganic base.
- a compound for use according to the present invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable acid.
- a compounds for use according to the present invention contains a free acid
- such salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable base.
- Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion.
- Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds for use according to the present invention and these form a further aspect of the present invention.
- solutions of the present compounds in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed.
- aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
- Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
- suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, syrup, phospholipids, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
- the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
- compositions formed by combining the compounds of the invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
- the formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
- compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents, and preserving agents in order to pro- vide pharmaceutically elegant and palatable preparations.
- Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically-acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example, starch, gelatine or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatine capsules where the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or a soft gelatine capsule wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- an oil medium for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide such as lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyl- eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example sodium carb
- the aqueous suspensions may also contain one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredient in a vegeta- ble oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as a liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipi- ents, for example, sweetening, flavouring, and colouring agents may also be present.
- the pharmaceutical compositions comprising a compound for use according to the present invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example a liquid paraffin, or a mixture thereof.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, leci- thin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, preservative and flavouring and colouring agent.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known methods using suitable dispersing or wetting agents and suspending agents described above.
- the sterile injectable preparation may also be a sterile in- jectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for ex- ample as a solution in 1 ,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conveniently employed as solvent or suspending medium.
- any bland fixed oil may be employed using synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- compositions may also be in the form of suppositories for rectal administration of the compounds of the present invention.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug.
- a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug.
- Such materials in- elude cocoa butter and polyethylene glycols, for example.
- compositions, ointments, jellies, solutions of suspensions, etc., containing the compounds of the present invention are contemplated.
- topical applications shall include mouth washes and gargles.
- the compounds for use according to the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes may be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
- solvates may form solvates with water or common organic solvents. Such solvates are also encompassed within the scope of the present invention.
- a pharmaceutical composition comprising a compound for use according to the present invention, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.
- a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
- a typical tablet which may be prepared by conventional tabletting techniques may contain:
- Active compound (as free compound or salt thereof) 5.0 mg
- the compounds of the invention may be administered to a patient which is a mammal, especially a human in need thereof.
- mammals include also animals, both domestic animals, e.g., household pets, and non-domestic animals such as wildlife.
- Any novel feature or combination of features described herein is considered essential to this invention.
- the present invention also relate to the below methods of preparing the compounds of the invention. [00348] The present invention is further illustrated in the following representative examples which are, however, not intended to limit the scope of the invention in any way.
- Preparative HPLC Column: 1.9 x 15 cm Waters XTerra RP-18. Buffer: linear gradient 5 - 95 % in 15 min, MeCN, 0.1 % TFA, flow rate of 15 ml/min. The pooled fractions are either evaporated to dryness in vacuo, or evaporated in vacuo until the MeCN is removed, and then frozen and freeze dried.
- MS mass spectrometry
- HPLC high pressure liquid chromatography
- RP reverse phase
- HPLC-MS high pressure liquid chromatography-mass spectrometry
- NMR nuclear magnetic resonance spectroscopy
- TLC thin layer chromatography
- DCM dichloromethane, CH 2 CI 2 , methylenechloride
- DIPEA ⁇ /, ⁇ /-diisopropylethylamine
- EDAC I -ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
- Et 2 O diethyl ether
- TFA trifluoroacetic acid
- CDCI 3 deuterio chloroform
- CD 3 OD tetradeuterio methanol
- NMR spectra were recorded at 300 and 400 MHz on a Bruker DRX300, DRX400 or AV400 instrument equipped with 5 mm selective-inverse (SEI, 1 H and 13 C), 5 mm broadband inverse (BBI, 1 H, broad-band) and 5 mm quadro nuclear (QNP, 1 H, 13 C) probeheads, respectively. Shifts ( ⁇ ) are given in parts per million (ppm) down field from tetramethylsilane as internal reference standard.
- the RP-purification was performed on a Gilson system (3 Gilson 306 pumps, Gil- son 170 DAD detector and a Gilson 215 liquid handler) using a Waters X-terra RP (10 ⁇ m, 30 mm x 150 mm) with gradient elution, 5 % to 95 % solvent B (0.05 % TFA in acetonitrile) in solvent A (0.05 % TFA in water) within 15 min, 40 mL/min, detection at 210 nm, temperature rt.
- the pooled fractions are either evaporated to dryness in vacuo, or evaporated in vacuo until the acetonitrile is removed, and then frozen and freeze dried.
- a benzimidazole of formula (II) wherein NR 3 R 4 corresponds to ring A defined above may be reacted with a carboxylic acid in the presence of coupling reagents (e.g., EDAC and HOBt) or an activated carboxylic acid of the formula (III) wherein R 1 is as defined above.
- This reaction may be carried out in a suitable solvent (e.g., dichloromethane) in the presence of a base (e.g., DIPEA) at ambient temperature.
- 4-Fluoro-3-nitrobenzoic acid may be reacted with an amine of formula (IV) wherein R 8 , R 9 , R 10 , R 11 and R 12 are as defined above.
- This reaction may be carried out in a suitable solvent (e.g., ethanol) in the presence of a base (e.g., DIPEA) at ambient temperature forming the secondary aniline of formula (V).
- a suitable solvent e.g., ethanol
- a base e.g., DIPEA
- the carboxylic acid of formula (V) then can be activated with HOBT and EDAC and reacted with an amine of the formula (Vl) wherein NR 3 R 4 is ring A as defined above.
- This reaction may be carried out in a suitable solvent (e.g., THF) in the presence of a base (e.g., DIPEA) at ambient temperature forming the compound of formula (VII).
- a suitable solvent e.g., methanol/dichloromethane
- a catalyst e.g., palladium on activated carbon
- Compounds of formula (VIII) may be reacted with an aldehyde of formula (IX) wherein R 2 is as defined above.
- This reaction may be carried out in a suitable solvent (e.g., NMP) in the presence of a drying agent (e.g., molecular sieve 4 A) at 5O 0 C to form compounds of formula (Ib).
- 4-Amino-3-nitrobenzoic acid can be activated with HOBT and EDAC and reacted with an amine of the formula (Vl) wherein NR 3 R 4 is ring A as defined above.
- This reaction may be carried out in a suitable solvent (e.g., THF) in the presence of a base (e.g., DIPEA) at ambient temperature to form the compound of formula (X).
- a suitable solvent e.g., THF
- a base e.g., DIPEA
- the nitro group of the formula (X) may be reduced by hydrogen under pressure in a mixture of methanol and dichloro- methane in presence of a catalyst (e.g., palladium on activated carbon) at ambient tempera- ture to form the diamine of the formula (Xl).
- a catalyst e.g., palladium on activated carbon
- (Xl) may be reacted with an aldehyde of the formula (IX) wherein R 2 is as defined above.
- This reaction may be carried out in NMP in the presence of a drying agent (e.g., molecular sieve 4 A) at 5O 0 C to form target product (Ic).
- a drying agent e.g., molecular sieve 4 A
- An indole of formula (XII) wherein R 3 , R 4 , and R 5 are as defined above, with NR 3 R 4 corresponding to ring A, may be reacted with an alky/benzyl halide of the formula (XIII) wherein R 1 is as defined above in the presence of base (e.g., sodium hydride).
- base e.g., sodium hydride
- This reaction may be carried out in a suitable solvent (e.g., DMF) at a temperature of up to reflux.
- reaction was quenched by the addition of water (5 ml_) and acidified to pH 2 with 1 N HCI followed by ex- traction with diethyl ether (2 x 10 ml_).
- the combined organic phases were washed with water (2 x 10 ml_), brine (10 ml_), dried (MgSO 4 ), filtered, and evaporated in vacuo affording 1 1 mg (1 1%) of the title compound as yellow oil.
- 1 -(2-Methylsulfanylmethoxy-ethyl)-1 H-benzoimidazole-5-carboxylic acid methyl ester A solution of 1 -(2-hydroxyethyl)-1 H-benzimidazole-5-carboxylic acid methyl ester (0.5 g. 2.27mmol) in a mixture of dry THF:DME (25 ml_ : 15 ml_) was cooled to 5 0 C. NaH (0.081 g, 3.4 mmol) was added and stirred for 30 min at the same temperature.
- Step-E 1 -(2-Methanesulfonylmethoxy-ethyl)-1 H-benzoimidazole- ⁇ -carboxylic acid methyl ester: A solution of 1 -(2-methylsulfanylmethoxyethyl)-1 H-benzimidazole-5-carboxylic acid methyl ester (3.0 g. 10.7mmoles) in methanol (30 ml_) was cooled to O 0 C and to this was added a solution of oxone (4.88 g, 7.94 mmoles) in water. The solution was stirred at the ambient temperature for 12 h. It was quenched with 5% sodium bicarbonate solution and extracted with EtOAc.
- Step-B 2-(2-Methanesulfonyl-ethyl)-isoindole-1 ,3-dione: To a solution of 2-(2-methylsulfanylethyl)-isoindole-1 ,3-dione (2.5 g, 1 1.30 mmol) in acetic acid (10 ml_) was added 30% hydrogen peroxide (6 ml_) at O 0 C. The reaction mixture was brought to room temp and stirred for 2 h. Excess hydrogen peroxide in the reaction mixture was quenched with a saturated solution of sodium sulphite, and the resulting solution extracted with CHCI 3 .
- Step-C 2-Methanesulfonyl-ethylamine: Hydrazine hydrate (15 ml_) was added to a solution of 2-(2-methanesulfonylethyl)-isoindole- 1 ,3-dione (3.123 g, 12.344 mmol) in a mixture of CHCI 3 -ethanol (:1 ) at O 0 C. It was then stirred overnight at room tremperature. It was filtered and the filtrate concentrated to give 2- Methanesulfonylethylamine (1 .2 g, 80%).
- 1 H NMR 300 MHz, CDCI 3 ) ⁇ 3.05 (t,2H), 3.15 (t, 2H), 3.0 (s, 3H).
- Step G 1 -(2-Methanesulfonyl-ethyl)-1 H-benzoimidazole-5-carboxylic acid (5-hydroxy-adamantan-2- yl)-amide:
- 3-Amino-4-(2-cyanoethylamino)-benzoic acid methyl ester To a solution of ammonium chloride (21 .7 g, 406.3 mmol) in water (200 ml_) was added 4-(2- cyanoethylamino)-3-nitro-benzoic acid methyl ester (6.1 g, 24.5 mmol) followed by zinc powder (42.8 g, 655.9 mmol). The mixture was heated to 60° C for 3 h. It was filtered hot and washed with EtOAc. The filtrate was further extracted with EtOAc and the combined organic phase washed with brine solution.
- Step-D 1 -(2-Cyanoethyl)-1 H-benzoimidazole-5-carboxylic acid:
- Step-E 3-[5-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzoimidazol-1 -yl]-propionitrile: To a solution of 1 -(2-cyanoethyl)-1 H-benzoimidazole-5-carboxylic acid (0.25 g, 1.16 mmol) in DMF (2.5 ml_) was added with stirring HOBt (0.17 g, 1 .27mmol) followed by exo- nortropinol hydrochloride (0.21 g, 1.27mmol), DIPEA (0.45 g, 3.48 mmol). EDCI.
- Step-D 1 -(2-Chloroethyl)-1 H-benzimidazole-5-carboxylic acid methyl ester:
- Step-E 1 -(2-Azidoethyl)-1 H-benzimidazole-5-carboxylic acid methyl ester:
- Step-H [1 -(2-Amino-ethyl)-1 H-benzoimidazol-5-yl]-(3-hydroxy-8-aza-bicyclo[3.2.1 ]oct-8-yl)- methanone:
- Steps A-F is similar to those used in example 13 above.
- Step-G [1 -(2-azidoethyl)-1 H-benzimidazol-5-yl]-(octahydroquinolin-1 -yl)methanone:
- [1 -(2-Aminoethyl)-1 H-benzimidazol-5-yl]-(octahydroquinolin-1 -yl)methanone To a solution of [1 -(2-azidoethyl)-1 H-benzimidazol-5-yl]-(octahydroquinolin-1 -yl)methanone (1 .8 g, 0.0051 mol) in methanol (10 ml_) was adde 10% Pd/C (0.2 g). The reaction mixture was hydrogenated at 3 kg pressure for 2 h.
- the catalyst was filtered over celite and the fil- trate was concentrated to give [1 -(2-aminoethyl)-1 H-benzimidazol-5-yl]-(octahydroquinolin-1 - yl)methanone (1 .5 g, 90%).
- Steps A-F is similar to those used in example 14 above.
- Steps A-F is similar to those used in example 15 above.
- Steps A-F is similar to those used in example 16 above.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008537122A JP2009513611A (en) | 2005-11-01 | 2006-11-01 | Pharmaceutical use of substituted amides |
EA200801492A EA200801492A1 (en) | 2005-11-01 | 2006-11-01 | PHARMACEUTICAL APPLICATION OF SUBSTITUTED AMIDES |
EP06807711A EP1945207A2 (en) | 2005-11-01 | 2006-11-01 | Pharmaceutical use of substituted amides |
BRPI0618051-5A BRPI0618051A2 (en) | 2005-11-01 | 2006-11-01 | pharmaceutical use of substituted amides |
CA002627307A CA2627307A1 (en) | 2005-11-01 | 2006-11-01 | Pharmaceutical use of substituted amides |
AU2006310519A AU2006310519A1 (en) | 2005-11-01 | 2006-11-01 | Pharmaceutical use of substituted amides |
US12/092,223 US8053431B2 (en) | 2005-11-01 | 2006-11-01 | Pharmaceutical use of substituted amides |
IL191034A IL191034A0 (en) | 2005-11-01 | 2008-04-27 | Pharmaceutical use of substituted amides |
US13/220,843 US20110312949A1 (en) | 2005-11-01 | 2011-08-30 | Pharmaceutical use of substituted amides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05110226 | 2005-11-01 | ||
EP05110226.7 | 2005-11-01 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/220,843 Continuation US20110312949A1 (en) | 2005-11-01 | 2011-08-30 | Pharmaceutical use of substituted amides |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007051811A2 true WO2007051811A2 (en) | 2007-05-10 |
WO2007051811A3 WO2007051811A3 (en) | 2008-01-24 |
Family
ID=36072052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/068017 WO2007051811A2 (en) | 2005-11-01 | 2006-11-01 | Pharmaceutical use of substituted amides |
Country Status (11)
Country | Link |
---|---|
US (2) | US8053431B2 (en) |
EP (1) | EP1945207A2 (en) |
JP (1) | JP2009513611A (en) |
KR (1) | KR20080069189A (en) |
CN (1) | CN101355938A (en) |
AU (1) | AU2006310519A1 (en) |
BR (1) | BRPI0618051A2 (en) |
CA (1) | CA2627307A1 (en) |
EA (1) | EA200801492A1 (en) |
IL (1) | IL191034A0 (en) |
WO (1) | WO2007051811A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017381A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
WO2009021740A2 (en) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2243479A2 (en) | 2009-04-20 | 2010-10-27 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8084646B2 (en) | 2006-11-02 | 2011-12-27 | Shionogi & Co., Ltd. | Process for production of hydroxyadamantaneamine |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8497281B2 (en) | 2009-11-06 | 2013-07-30 | Vitae Pharmaceuticals, Inc. | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
US8524894B2 (en) | 2009-06-04 | 2013-09-03 | Laboratorios Salvat, S.A. | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 |
US8686149B2 (en) | 2010-11-05 | 2014-04-01 | Boehringer-Ingelheim International Gmbh | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
US9708268B2 (en) | 2012-04-30 | 2017-07-18 | Innov17 Llc | ROR modulators and their uses |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8138342B2 (en) * | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
CA2627306A1 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma, Inc. | Pharmaceutical use of substituted amides |
CA2646588A1 (en) * | 2006-03-21 | 2007-09-27 | High Point Pharmaceuticals, Llc | Adamantane derivatives for the treatment of the metabolic syndrome |
BRPI0710669A2 (en) | 2006-04-07 | 2011-08-16 | High Point Pharmaceuticals Llc | 11b-hydroxysteroid dehydrogenase type 1 active compounds |
US8048908B2 (en) * | 2006-07-13 | 2011-11-01 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1878721A1 (en) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
US20110003856A1 (en) * | 2007-02-23 | 2011-01-06 | Soren Ebdrup | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
CN101679217A (en) | 2007-02-23 | 2010-03-24 | 高点制药有限责任公司 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
US8334305B2 (en) * | 2007-02-23 | 2012-12-18 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase |
WO2008101885A1 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
KR20100015414A (en) * | 2007-03-09 | 2010-02-12 | 하이 포인트 파마슈티칼스, 엘엘씨 | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
CA2681934A1 (en) * | 2007-03-28 | 2008-10-02 | High Point Pharmaceuticals, Llc | 11beta-hsd1 active compounds |
EP2152081B1 (en) * | 2007-04-11 | 2012-10-24 | High Point Pharmaceuticals, LLC | Novel compounds |
ES2393230T3 (en) * | 2007-04-24 | 2012-12-19 | High Point Pharmaceuticals, Llc | Pharmaceutical use of substituted amides |
CA2744383C (en) * | 2008-11-21 | 2017-04-25 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
CN103373951B (en) * | 2012-04-28 | 2016-03-09 | 上海医药工业研究院 | A kind of preparation method of lapatinib intermediate |
MX355873B (en) | 2013-03-13 | 2018-05-02 | Unilever Nv | Cosmetic compositions with tricyclodecane amides. |
WO2014139965A1 (en) | 2013-03-13 | 2014-09-18 | Unilever Plc | Photoprotective compositions with tricyclodecane amides |
EP2968082B1 (en) | 2013-03-13 | 2017-02-01 | Unilever PLC | Prolonged delivery of certain fragrance components from personal care compositions |
EA031458B1 (en) | 2013-12-09 | 2019-01-31 | Юнилевер Н.В. | Process of making adamantanamides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089896A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
WO2004089471A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1025881B (en) | 1955-11-26 | 1958-03-13 | Bayer Ag | Process for the production of condensation products |
US2913454A (en) | 1956-11-23 | 1959-11-17 | Schenley Ind Inc | Certain cycloalkanotriazoles, process and intermediates |
US3723442A (en) * | 1970-12-31 | 1973-03-27 | Yoshitomi Pharmaceutical | 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes |
US3784551A (en) * | 1971-07-08 | 1974-01-08 | Yoshitomi Pharmaceutical | 2-oxo-1,4-dioxa-8-azaspiro (4.5) decanes and related compounds |
FR2456731A1 (en) | 1979-05-16 | 1980-12-12 | Choay Sa | Guanidino and amino benzoate(s) and phenyl sulphonate(s) - and related cpds. inhibit protease(s) and have bacteriostatic and fungistatic activity |
US4350696A (en) * | 1980-03-08 | 1982-09-21 | Pfizer Inc. | Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof |
AU557300B2 (en) * | 1982-03-16 | 1986-12-18 | Farmitalia Carlo Erba S.P.A. | Substituted 1h-pyrazolo(1,5-alpha)pyrimidines and processes for their preparation |
DE3445377A1 (en) * | 1983-12-23 | 1985-07-04 | Sandoz-Patent-GmbH, 7850 Lörrach | CARBOCYLIC AND HETEROCYCLIC CARBONIC ACID ESTERS AND AMIDES OF BRIDGED AND NON-BRIDGED CYCLIC NITROCYLINE AMINES OR ALCOHOLS |
US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
FI864875A0 (en) * | 1986-11-28 | 1986-11-28 | Orion Yhtymae Oy | NYA FARMAKOLOGISKT AKTIVA FOERENINGAR, DESSA INNEHAOLLANDE KOMPOSITIONER SAMT FOERFARANDE OCH MELLANPRODUKTER FOER ANVAENDNING VID FRAMSTAELLNING AV DESSA. |
YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
US4851423A (en) * | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
US5272167A (en) * | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
US5225402A (en) * | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
GB8904174D0 (en) * | 1989-02-23 | 1989-04-05 | British Bio Technology | Compounds |
US5169850A (en) * | 1990-01-22 | 1992-12-08 | American Cyanamid Company | N-(dialkylamino)methylene)-substituted pyrazolo(1,5-a)-pyrimidine-3-carboxamides and N-(dialkylamino)methylene-substituted-4,5-dihydropyrazolo-(1,5-a)-pyrimidine-3-carboxamides |
US5432191A (en) | 1990-02-12 | 1995-07-11 | The Center For Innovative Technology | Allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
US5591892A (en) * | 1990-02-12 | 1997-01-07 | Center For Innovative Technology | Allosteric modifiers of hemoglobin |
US5290803A (en) * | 1990-02-12 | 1994-03-01 | The Center Of Innovative Technology | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
US5677330A (en) * | 1990-02-12 | 1997-10-14 | The Center For Innovative Technology | Medical uses of allosteric hemoglobin modifier compounds in patient care |
US5648375A (en) * | 1990-02-12 | 1997-07-15 | Virginia Commonwealth University | Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers |
US5731454A (en) * | 1990-02-12 | 1998-03-24 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
US5049695A (en) * | 1990-02-12 | 1991-09-17 | Center For Innovative Technology | Allosteric hemoglobin modifiers |
US5705521A (en) * | 1990-02-12 | 1998-01-06 | The Center For Innovative Technology | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors |
US5382680A (en) * | 1990-12-07 | 1995-01-17 | The Center For Innovative Technology | Allosteric hemoglobin modifier compounds |
US5122539A (en) * | 1990-02-12 | 1992-06-16 | Center For Innovative Technology | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
US5872282A (en) * | 1990-12-07 | 1999-02-16 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin |
FR2677984B1 (en) * | 1991-06-21 | 1994-02-25 | Elf Sanofi | N-SUBSTITUTED IMIDAZOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
US5258407A (en) * | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5356904A (en) * | 1992-10-07 | 1994-10-18 | Merck & Co., Inc. | Carbostyril oxytocin receptor antagonists |
ATE236164T1 (en) * | 1992-12-04 | 2003-04-15 | Janssen Pharmaceutica Nv | ANTIALLERGIC TRIAZOLOBENZAZEPINE DERIVATIVES |
US5571813A (en) * | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
US5395846A (en) * | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
FR2708608B1 (en) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them. |
WO1995004720A2 (en) * | 1993-08-10 | 1995-02-16 | Black James Foundation | Gastrin and cck receptor ligands |
US5426105A (en) * | 1993-09-24 | 1995-06-20 | G.D. Searle & Co. | Conformationally restricted angiotensin II antagonists |
US5674879A (en) * | 1993-09-24 | 1997-10-07 | G.D. Searle & Co. | Compositions including and methods of using conformationally restricted angiotensin II antagonist |
DE4338784A1 (en) | 1993-11-12 | 1995-05-18 | Langhals Heinz | Perylene-3,4-di:carboximide(s) and reaction prods. useful as fluorescent dye |
TW279860B (en) * | 1993-11-12 | 1996-07-01 | Ciba Geigy Ag | |
GB9409150D0 (en) * | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
WO1995032949A1 (en) * | 1994-05-27 | 1995-12-07 | James Black Foundation Limited | Gastrin and cck antagonists |
US5795907A (en) * | 1994-05-27 | 1998-08-18 | James Black Foundation Limited | Gastin and CCK receptor ligands |
AU6874096A (en) * | 1995-08-30 | 1997-03-19 | Bayer Aktiengesellschaft | Acylaminosalicylic acid amides and their uses as pesticides |
FR2741878B1 (en) * | 1995-12-01 | 1998-01-09 | Cird Galderma | BIAROMATIC COMPOUNDS CARRYING AN ADAMANTYL ORTHO GROUP, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES THEREOF |
TW359669B (en) * | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
US6124289A (en) * | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
BR9809288A (en) * | 1997-04-22 | 2001-08-07 | Cocensys Inc | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and their use |
US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6521641B1 (en) * | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
US6541477B2 (en) * | 1999-08-27 | 2003-04-01 | Scios, Inc. | Inhibitors of p38-a kinase |
US6476075B1 (en) * | 1999-09-23 | 2002-11-05 | G.D. Searle & Co. | Use of substituted N, N-bis-benzyl aminoalcohol compounds inhibiting cholesteryl ester transfer protein activity |
AUPQ309399A0 (en) | 1999-09-28 | 1999-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Benzothiazoline derivatives |
US6482829B2 (en) * | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US6833371B2 (en) * | 2001-11-01 | 2004-12-21 | Icagen, Inc. | Pyrazolopyrimidines |
JP2003286171A (en) | 2002-03-28 | 2003-10-07 | Sumitomo Pharmaceut Co Ltd | Par inhibitor |
WO2003087037A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
JP4202319B2 (en) * | 2002-07-29 | 2008-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | New benzodioxole |
US7186735B2 (en) * | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
EP1562925B1 (en) * | 2002-11-07 | 2007-01-03 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
KR20050115252A (en) * | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | Pyrazolo[1,5-a]pyrimidine derivatives |
CA2517166A1 (en) * | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists |
US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
US20070270408A1 (en) * | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
US7700583B2 (en) * | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
US7501405B2 (en) * | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
JP2006522747A (en) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | Pharmaceutical use of condensed 1,2,4-triazole |
EP1651595A2 (en) * | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
WO2005037199A2 (en) * | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
US20050261302A1 (en) * | 2004-04-29 | 2005-11-24 | Hoff Ethan D | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application |
WO2006016882A2 (en) * | 2004-07-08 | 2006-02-16 | Ndsu Research Foundation | Methods and materials for enhancing the effects of protein modulators |
US8138342B2 (en) * | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
JP5133702B2 (en) * | 2005-01-05 | 2013-01-30 | アボット・ラボラトリーズ | Inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme |
BRPI0606256A2 (en) * | 2005-01-05 | 2009-06-09 | Abbott Lab | 11-beta-hydroxysteroid dehydrogenase type i enzyme inhibitors, use and pharmaceutical composition comprising the same |
CN1736485A (en) | 2005-06-29 | 2006-02-22 | 上海美迪西生物医药有限公司 | Use of vanillin receptor agonist in preparation of product for resisting Alzheimer disease |
CA2627306A1 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma, Inc. | Pharmaceutical use of substituted amides |
JP5089185B2 (en) | 2006-02-02 | 2012-12-05 | 大塚製薬株式会社 | Collagen production inhibitor. |
CA2646588A1 (en) * | 2006-03-21 | 2007-09-27 | High Point Pharmaceuticals, Llc | Adamantane derivatives for the treatment of the metabolic syndrome |
BRPI0710669A2 (en) * | 2006-04-07 | 2011-08-16 | High Point Pharmaceuticals Llc | 11b-hydroxysteroid dehydrogenase type 1 active compounds |
CA2655282A1 (en) | 2006-06-16 | 2007-12-21 | High Point Pharmaceuticals, Llc | Pharmaceutical use of substituted piperidine carboxamides |
EP1878721A1 (en) | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
CN101679217A (en) * | 2007-02-23 | 2010-03-24 | 高点制药有限责任公司 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
US20110003856A1 (en) * | 2007-02-23 | 2011-01-06 | Soren Ebdrup | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
US8334305B2 (en) | 2007-02-23 | 2012-12-18 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase |
WO2008101885A1 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
KR20100015414A (en) * | 2007-03-09 | 2010-02-12 | 하이 포인트 파마슈티칼스, 엘엘씨 | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
CA2681934A1 (en) * | 2007-03-28 | 2008-10-02 | High Point Pharmaceuticals, Llc | 11beta-hsd1 active compounds |
EP2152081B1 (en) * | 2007-04-11 | 2012-10-24 | High Point Pharmaceuticals, LLC | Novel compounds |
ES2393230T3 (en) * | 2007-04-24 | 2012-12-19 | High Point Pharmaceuticals, Llc | Pharmaceutical use of substituted amides |
-
2006
- 2006-11-01 JP JP2008537122A patent/JP2009513611A/en not_active Withdrawn
- 2006-11-01 KR KR1020087011701A patent/KR20080069189A/en not_active Application Discontinuation
- 2006-11-01 AU AU2006310519A patent/AU2006310519A1/en not_active Abandoned
- 2006-11-01 WO PCT/EP2006/068017 patent/WO2007051811A2/en active Application Filing
- 2006-11-01 US US12/092,223 patent/US8053431B2/en not_active Expired - Fee Related
- 2006-11-01 BR BRPI0618051-5A patent/BRPI0618051A2/en not_active Application Discontinuation
- 2006-11-01 CA CA002627307A patent/CA2627307A1/en not_active Abandoned
- 2006-11-01 EA EA200801492A patent/EA200801492A1/en unknown
- 2006-11-01 CN CNA2006800502389A patent/CN101355938A/en active Pending
- 2006-11-01 EP EP06807711A patent/EP1945207A2/en not_active Withdrawn
-
2008
- 2008-04-27 IL IL191034A patent/IL191034A0/en unknown
-
2011
- 2011-08-30 US US13/220,843 patent/US20110312949A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089896A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
WO2004089471A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
WO2004089470A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
Non-Patent Citations (1)
Title |
---|
FOTSCH C ET AL: "11[beta]-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases" EXPERT OPINION ON THERAPEUTIC PATENTS 2005 UNITED KINGDOM, vol. 15, no. 3, 2005, pages 289-303, XP002376609 ISSN: 1354-3776 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017381A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
US8084646B2 (en) | 2006-11-02 | 2011-12-27 | Shionogi & Co., Ltd. | Process for production of hydroxyadamantaneamine |
US8524951B2 (en) | 2006-11-02 | 2013-09-03 | Shionogi & Co., Ltd. | Process for production of hydroxyadamantaneamine |
WO2009021740A2 (en) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2243479A2 (en) | 2009-04-20 | 2010-10-27 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
US8507493B2 (en) | 2009-04-20 | 2013-08-13 | Abbvie Inc. | Amide and amidine derivatives and uses thereof |
US8822452B2 (en) | 2009-06-04 | 2014-09-02 | Laboratorios Salvat, S.A. | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 |
US8524894B2 (en) | 2009-06-04 | 2013-09-03 | Laboratorios Salvat, S.A. | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
US9663470B2 (en) | 2009-11-06 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
US9328072B2 (en) | 2009-11-06 | 2016-05-03 | Vitae Pharmaceuticals, Inc. | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
US8497281B2 (en) | 2009-11-06 | 2013-07-30 | Vitae Pharmaceuticals, Inc. | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
US8686149B2 (en) | 2010-11-05 | 2014-04-01 | Boehringer-Ingelheim International Gmbh | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
US9120769B2 (en) | 2010-11-05 | 2015-09-01 | Boehringer-Ingelheim International Gmbh | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9708268B2 (en) | 2012-04-30 | 2017-07-18 | Innov17 Llc | ROR modulators and their uses |
Also Published As
Publication number | Publication date |
---|---|
JP2009513611A (en) | 2009-04-02 |
BRPI0618051A2 (en) | 2011-08-16 |
EA200801492A1 (en) | 2008-10-30 |
AU2006310519A1 (en) | 2007-05-10 |
CA2627307A1 (en) | 2007-05-10 |
US20090118259A1 (en) | 2009-05-07 |
IL191034A0 (en) | 2009-08-03 |
CN101355938A (en) | 2009-01-28 |
US8053431B2 (en) | 2011-11-08 |
KR20080069189A (en) | 2008-07-25 |
WO2007051811A3 (en) | 2008-01-24 |
US20110312949A1 (en) | 2011-12-22 |
EP1945207A2 (en) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8053431B2 (en) | Pharmaceutical use of substituted amides | |
US8153798B2 (en) | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors | |
EP1615698B1 (en) | New amide derivatives and pharmaceutical use thereof | |
US8138342B2 (en) | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | |
US7700583B2 (en) | 11β-hydroxysteroid dehydrogenase type 1 active compounds | |
US8048908B2 (en) | 11β-hydroxysteroid dehydrogenase type 1 active compounds | |
WO2007051810A2 (en) | Pharmaceutical use of substituted amides | |
WO2004089471A2 (en) | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF | |
MX2008005653A (en) | Pharmaceutical use of substituted amides | |
MX2008005322A (en) | Pharmaceutical use of substituted amides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006310519 Country of ref document: AU Ref document number: 12008500957 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2627307 Country of ref document: CA Ref document number: 567660 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 191034 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2008537122 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/005653 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006310519 Country of ref document: AU Date of ref document: 20061101 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006310519 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087011701 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006807711 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08054219 Country of ref document: CO Ref document number: 4561/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200801492 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680050238.9 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006807711 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12092223 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0618051 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080429 |